Abstract
Gene Logic began operations in 1996 as one of the first companies to envision high quality gene expression data as a commercial resource. To this end it began with a marriage of its patented READS (restriction endonucleolytic analysis of differentially expressed sequences) technology, a differential-display based approach to monitoring changes in gene expression, with unique expertise in bioinformatics and database construction. In January 1999, Gene Logic became one of the early adopters of the Affymetrix GeneChip® probe array, and began building its GeneExpress® gene expression database product using data from that system. In fact, Gene Logic worked closely with Affymetrix to refine procedures and analysis, as well as developing its own sample procurement and storage procedures, and the result was a premier, high quality, well annotated database of gene expression data from clinical samples. The resulting platform allowed, for example, both target discovery and the investigation of tumor differences at the molecular level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Path from Biomarker Discovery to Regulatory Qualification
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
